0000000000756810

AUTHOR

J. Błaszczyk

showing 5 related works from this author

Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)

2016

Abstract Objective Ovarian cancer comprises several histological groups with widely differing levels of survival. We aimed to explore international variation in survival for each group to help interpret international differences in survival from all ovarian cancers combined. We also examined differences in stage-specific survival. Methods The CONCORD programme is the largest population-based study of global trends in cancer survival, including data from 60 countries for 695,932 women (aged 15–99years) diagnosed with ovarian cancer during 1995–2009. We defined six histological groups: type I epithelial, type II epithelial, germ cell, sex cord-stromal, other specific non-epithelial and non-sp…

0301 basic medicineOncologySettore MED/42 - Igiene Generale E Applicata0302 clinical medicinemorphology80 and overStage (cooking)Aged 80 and overOvarian Neoplasmseducation.field_of_studyepidemiology; histology; morphology; ovarian cancer; stage; survival; Adolescent; Adult; Aged; Aged 80 and over; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Oncology; Obstetrics and GynecologyObstetrics and Gynecologyepidemiology; histology; morphology; ovarian cancer; stage; survivalMiddle AgedTransitional cell carcinomaovarian cancerOncology030220 oncology & carcinogenesisClear cell carcinomaepidemiologyFemaleHumanAdultmedicine.medical_specialtyAdolescentPopulationSocio-culturalesurvivalArticlehistology03 medical and health sciencesInternal medicinemedicineHumansovarian cancer epidemiology survival stage morphology histologyeducationepidemiology ; histology ; morphology ; ovarian cancer ; stage ; survivalCancer stagingAgedNeoplasm StagingGynecologybusiness.industryOvarian NeoplasmCancermedicine.diseasestageCancer registry030104 developmental biologyOvarian cancerbusiness
researchProduct

Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting.

2017

The management of patients with mesothelioma and thymic malignancy requires continuous multidisciplinary expertise at any step of the disease. A dramatic improvement in our knowledge has occurred in the last few years, through the development of databases, translational research programs, and clinical trials. Access to innovative strategies represents a major challenge, as there is a lack of funding for clinical research in rare cancers and their rarity precludes the design of robust clinical trials that could lead to specific approval of drugs. In this context, patient-centered initiatives, such as the establishment of dedicated networks, are warranted. International societies, such as IMI…

0301 basic medicineMesotheliomamedicine.medical_specialtyInternational CooperationPleural NeoplasmsMEDLINESocio-culturaleContext (language use)Translational researchDiseaseSocial Networking03 medical and health sciences0302 clinical medicineMultidisciplinary approachMedicineHumansMesotheliomaPleural NeoplasmIntensive care medicinebusiness.industryGeneral MedicineThymus Neoplasmsmedicine.diseaseClinical trialEuropeSurvival Rate030104 developmental biologyClinical researchOncology030220 oncology & carcinogenesisSurgery; OncologySurgerybusinessDelivery of Health Caremesothelioma thymic tumours clinical trialsHumanEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study

2017

Background: Rare cancers pose challenges for diagnosis, treatments, and clinical decision making. Information about rare cancers is scant. The RARECARE project defined rare cancers as those with an annual incidence of less than six per 100 000 people in European Union (EU). We updated the estimates of the burden of rare cancers in Europe, their time trends in incidence and survival, and provide information about centralisation of treatments in seven European countries. Methods: We analysed data from 94 cancer registries for more than 2 million rare cancer diagnoses, to estimate European incidence and survival in 2000–07 and the corresponding time trends during 1995–2007. Incidence was calcu…

Male0301 basic medicinePathologypopulation-based registriesCancer Care Facilities; Delivery of Health Care; Europe; Female; Hospitalization; Humans; Incidence; Male; Neoplasms; Rare Diseases; Registries; Survival Rate; Oncology0302 clinical medicineNeoplasmsMedicineRegistriesmedia_commonTumors -- Treatment -- Europeeducation.field_of_studyRelative survivalIncidenceIncidence (epidemiology)RARECARE projectEuropeHospitalizationSurvival RateOncology030220 oncology & carcinogenesis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalemedicine.medical_specialtyHealth surveysPopulationSocio-culturaleCancer Care Facilities03 medical and health sciencesRare DiseasesSDG 3 - Good Health and Well-beingHumansmedia_common.cataloged_instanceCancer -- MortalityRisk factorEuropean unioneducationSurvival rateOncology cancer burden incidence rare cancerpopulation-based registriesrare cancers cancer registry RARECAREbusiness.industryRare cancerCancer -- Patients -- Long-term careCancer registry030104 developmental biologycancer burdenbusinessDelivery of Health CareDemographyRare disease
researchProduct

Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival esti…

2017

Abstract Background Cancer registries (CRs) are fundamental for estimating cancer burden, evaluating screening and monitoring health service performance. Stage at diagnosis—an essential information item collected by CRs—has been made available, for the first time, by CRs participating in EUROCARE-5. We analysed the quality of this information and estimated stage-specific survival across Europe for CRs with good data quality. Data and methods Sixty-two CRs sent stage (as TNM, condensed TNM or extent of disease) for 15 cancers diagnosed in 2000–2007. We assessed the quality, partly by comparing stage according to the three systems. We also developed procedures to reconstruct stage (categories…

Malemedicine.medical_specialtyCancer ResearchStage at diagnosiSurvivalConcordanceCancer registrieCancer registries ; Data quality ; Stage at diagnosis ; SurvivalSocio-culturaleReproducibility of ResultPredictive Value of TestCancer registries; Data quality; Stage at diagnosis; Survival; Data Accuracy; Europe; Female; Humans; Male; Neoplasm Metastasis; Neoplasms; Predictive Value of Tests; Reproducibility of Results; Survival Analysis; Neoplasm Staging; Registries; Oncology; Cancer Research03 medical and health sciences0302 clinical medicineBreast cancerPredictive Value of TestsNeoplasmsmedicineotorhinolaryngologic diseasesCancer registriesHumans030212 general & internal medicineRegistriesStage (cooking)Neoplasm MetastasisIntensive care medicineSurvival analysisCancer stagingNeoplasm Stagingbusiness.industryData qualityReproducibility of ResultsStage at diagnosismedicine.diseaseSurvival AnalysisCancer registryData AccuracyClinical trialNeoplasm MetastasiEuropeOncology030220 oncology & carcinogenesisData qualityNeoplasmFemaleSurvival AnalysibusinessHumanEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5

2017

Background: Incidence rates of thyroid cancer (TC) increased in several countries during the last 30 years, while mortality rates remained unchanged, raising important questions for treatment and follow-up of TC patients. This study updates population-based estimates of relative survival (RS) after TC diagnosis in Europe by sex, country, age, period and histology.Methods: Data from 87 cancer registries in 29 countries were extracted from the EUROCARE-5 dataset. One-and 5-year RS were estimated using the cohort approach for 86,690 adult TC patients diagnosed in 2000-2007 and followed-up to 12/31/2008. RS trends in 1999-2007 and 10-year RS in 2005-2007 were estimated using the period approach…

RegistrieMaleCancer ResearchIMPACTCancer registrie[SDV]Life Sciences [q-bio]Papillary0302 clinical medicineQUALITY-OF-LIFEResidence CharacteristicsAdenocarcinoma FollicularCancer registriesRegistriesThyroid cancerThyroid Neoplasmeducation.field_of_studyRelative survivalIncidence (epidemiology)Mortality rateIncidenceDiagnosis-Related GroupCancer registries; EUROCARE; Europe; Papillary; Relative survival; Thyroid cancer; Adenocarcinoma Follicular; Adolescent; Adult; Aged; Carcinoma; Carcinoma Papillary; Diagnosis-Related Groups; Europe; Female; Humans; Incidence; Male; Middle Aged; Registries; Residence Characteristics; Sex Distribution; Thyroid Neoplasms; Young Adult; Oncology; Cancer ResearchMiddle AgedPREVALENCE3. Good healthEuropeOncologyThyroid Cancer Papillary030220 oncology & carcinogenesisCohortFemaleEUROCAREHumanAdultmedicine.medical_specialtyAdolescentPopulationGEOGRAPHICAL-DISTRIBUTIONUNITED-STATESSocio-culturale030209 endocrinology & metabolismAdenocarcinomaRelative survivalThyroid cancerRECENT TRENDS03 medical and health sciencesYoung AdultMANAGEMENTmedicineHumansThyroid NeoplasmsSex DistributioneducationSurvival rateDiagnosis-Related GroupsAgedbusiness.industryMORTALITYCarcinomaFollicularCancer registries; EUROCARE; Europe; Papillary; Relative survival; Thyroid cancer; Oncology; Cancer Researchmedicine.diseaseCarcinoma PapillaryCancer registrySurgeryMICROCARCINOMAResidence CharacteristicCancer registries ; EUROCARE ; Europe ; Papillary ; Relative survival ; Thyroid cancerbusinessDemography
researchProduct